Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Antiviral treatment of chronic hepatitis C in clinical routine.

Maieron A, Metz-Gercek S, Hackl F, Ziachehabi A, Fuchsteiner H, Luger C, Mittermayer H, Schöfl R.

Wien Klin Wochenschr. 2010 Apr;122(7-8):237-42. doi: 10.1007/s00508-010-1364-7.

PMID:
20503023
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

3.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
4.

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.

Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.

World J Gastroenterol. 2014 Nov 28;20(44):16726-33. doi: 10.3748/wjg.v20.i44.16726.

5.

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C.

Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):597-609. doi: 10.1007/s10096-016-2576-1. Epub 2016 Feb 6.

6.

Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.

El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.

World J Gastroenterol. 2014 Apr 28;20(16):4681-91. doi: 10.3748/wjg.v20.i16.4681.

7.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
8.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

9.
10.
11.

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.

Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11.

PMID:
21281434
12.
13.

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.

Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.

World J Gastroenterol. 2015 Apr 7;21(13):3904-11. doi: 10.3748/wjg.v21.i13.3904.

15.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
16.

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.

Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.

World J Gastroenterol. 2015 May 14;21(18):5496-504. doi: 10.3748/wjg.v21.i18.5496.

17.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.

Dogan UB, Atabay A, Akin MS, Yalaki S.

Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1082-5. doi: 10.1097/MEG.0b013e32836076d1.

PMID:
23524524
18.

Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.

Dogan UB, Akin MS, Yalaki S.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1317-20. doi: 10.1097/MEG.0b013e328362797b.

PMID:
23680912
19.

Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.

Taha AA, El-Ray A, El-Ghannam M, Mounir B.

Can J Gastroenterol. 2010 Oct;24(10):597-602.

20.

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

Bourlière M, Ouzan D, Rosenheim M, Doffoël M, Marcellin P, Pawlotsky JM, Salomon L, Fagnani F, Rouanet S, Pinta A, Vray M.

Antivir Ther. 2012;17(1):101-10. doi: 10.3851/IMP1935.

PMID:
22267474

Supplemental Content

Support Center